Kalvista Pharmaceuticals Inc

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. The company is a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. Its offerings include sebetralstat, an oral on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. Formerly known as KalVista Pharmaceuticals Ltd., it changed its name to KalVista Pharmaceuticals, Inc. in November 2016 and is headquartered in Framingham, Massachusetts. As of June 11, 2026, it operates as a subsidiary of Chiesi Farmaceutici S.p.A.